JCR Pharmaceuticals

JCR Pharmaceuticals

JCR has been proactively engaged in research and development (R&D) of biopharmaceuticals based on recombinant DNA technologies. Learn more

Launch date
Employees
Market cap
$638m
Enterprise valuation
$673m (Public information from Sep 2024)
Kobe Hyogo Prefecture (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
JPY2021202220232024202520262027
Revenues30.1b51.1b34.3b42.9b41.6b41.3b41.8b
% growth21 %70 %(33 %)25 %(3 %)(1 %)1 %
EBITDA10.5b22.5b7.5b10.5b8.9b7.8b7.7b
% EBITDA margin35 %44 %22 %25 %22 %19 %18 %
Profit6.9b14.5b3.8b5.5b4.9b4.7b5.2b
% profit margin23 %28 %11 %13 %12 %11 %12 %
EV / revenue14.5x5.2x5.4x2.6x2.0x2.0x2.0x
EV / EBITDA41.6x11.8x24.9x10.6x9.3x10.6x10.6x

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound

N/A

Seed
N/A

N/A

IPO
Total Funding-

Recent News about JCR Pharmaceuticals

Edit
More about JCR Pharmaceuticalsinfo icon
Edit

JCR Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for rare and intractable diseases. Operating primarily in the healthcare and biotechnology sectors, JCR Pharmaceuticals serves patients, healthcare providers, and research institutions. The company's business model focuses on leveraging advanced cell and gene therapy technologies to create effective and targeted treatments. Revenue is generated through the sale of proprietary drugs, licensing agreements, and collaborative research partnerships. JCR Pharmaceuticals aims to address unmet medical needs by providing cutting-edge solutions that improve patient outcomes and quality of life.

Keywords: biopharmaceutical, rare diseases, intractable diseases, cell therapy, gene therapy, healthcare, biotechnology, innovative treatments, patient outcomes, research partnerships.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by JCR Pharmaceuticals

Edit
ArmaGen Technologies
ACQUISITION by JCR Pharmaceuticals Mar 2020